Want to join the conversation?
Biotechnology pioneer $AMGN said it recorded 17% growth from its in-line brands, including Enbrel, Prolia, XGEVA, Sensipar, Vectibix and Nplate. Together, these brands generated $11Bil. The company stated that its legacy medicines also performed well and these continue to be strong cash flow generators.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.